DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

Anabasum (JBT-101)

Phase Two

Phase Two

Therapeutic Approach

Anti-Inflammatory

Anabasum JBT-101 (Resunab™) is an oral drug that is aimed at promoting the resolution of inflammation. It is thought to increase production of anti-inflammatory molecules while reducing production of molecules that increase inflammation. Reduction of inflammation helps prevent permanent tissue damage in the lungs.

Status

A phase 2 study completed in 2016 showed that anabasum reduced the rate of acute pulmonary exacerbations in adults with CF.

Sponsor

This program is sponsored by Corbus and partially funded by the Cystic Fibrosis Foundation Therapeutics (CFFT). It is being conducted within CFFT's Therapeutics Development Network.

Contact us about Anabasum (JBT-101) >